BACKGROUND: Implantable cardioverter-defibrillator (ICD) recipients require close follow-up that can be difficult for patients who have to travel long distances for clinic follow-up. We aimed to compare clinical outcomes between ICD patients followed-up in a telemedicine videoconferencing clinic (TMVC) and a conventional in-person clinic (CIC). We hypothesized that outcomes of patients followed in the TMVC are noninferior to the CIC.
I
mplantable cardioverter-defibrillators (ICDs) are increasingly used for primary and secondary prevention of sudden cardiac death. [1] [2] [3] [4] [5] The estimated number of ICDs and cardiac resynchronization therapy (CRT) devices implanted in North America in 2007 was 234 748 and 148 092, respectively, according to the 2008 Heart Rhythm Society and European Heart Rhythm Association consensus statement on the monitoring of cardiovascular implantable electronic devices. 6, 7 The minimum frequency of in-person evaluation or remote interrogation should be every 3 to 6 months for ICD/CRT-defibrillator devices according to practice guidelines. 6, 8 The logistics of monitoring these devices have placed a substantial and increasing burden not only on the cardiovascular community but also on ICD recipients who sometimes have to travel long distances for their device clinic follow-up appointments.
Telehealth or telemedicine (TM) uses information technology and telecommunication to provide health care. Several studies have shown that telehealth interventions can improve clinical outcomes in a variety of conditions. [9] [10] [11] [12] The veterans administration (VA) has used TM health programs to monitor veterans with diabetes mellitus, spinal cord injuries, pressure ulcers, and in rehabilitation efforts. 13, 14 The primary goal of an ICD follow-up clinic is to monitor the function of the devices and to optimize medical therapy and programming parameters to reduce the burden of arrhythmias, both spontaneous and device induced, and minimize appropriate and inappropriate ICD therapies. The goal of this study is to determine whether outcomes in patients followed via video conferencing using TM are noninferior to those followed in person.
WHAT IS KNOWN
• Implantable cardioverter-defibrillator recipients require close follow-up. The logistics of monitoring these devices place a substantial and increasing burden on the cardiovascular community and implantable cardioverter-defibrillator recipients.
• Follow-up can be difficult for patients and providers who have to travel long distances for their device clinic follow-up appointments.
• Telehealth interventions can improve clinical outcomes.
WHAT THE STUDY ADDS
• Telemedicine implantable cardioverter-defibrillator follow-up using video conferencing offers a longterm device follow-up model that leads to clinical outcomes that are noninferior to the conventional in-person follow-up.
• This model has the potential for cost savings in reducing travel time and cost for patients and providers, as well as a solution for constrained clinic space and resource utilization.
METHODS

Study Population
The Portland veterans affairs healthcare system (VAPORHCS) provides for TM video-conferencing clinic (TMVC) follow-up for patients who reside in Seattle (WA), Roseburg (OR), Boise (ID), Walla Walla (WA), and Anchorage (AK). TMVC visits replace conventional in-person clinic (CIC) visits. Therefore, patients are not required to travel to the VAPORHCS. The TMVC device model includes a registered nurse plus a technical support representative from the ICD companies or a nurse practitioner with expertise in device interrogation on the patient side communicating via an audio and a video link with a physician or nurse practitioner at VAPORHCS. The practitioner in Portland has the option to view a room camera, a direct video feed from the programmer, or a document camera as needed. All providers in the TMVC complete training courses (video and web courses) on various aspects of participating in TM clinics. All clinic data are entered into a prospective database. The study population included patients who received an ICD/ CRT-defibrillator device at the VAPORHCS between January 2001 and January 2013 and were followed-up in either the TMVC via video conferencing or the CIC in Portland, OR. The study proposal was reviewed by the VAPORHCS Institutional Review Board and was granted approval and access to patients' medical records. A priori identified study variables were extracted from the VA electronic medical record and a prospective clinical database with data on ICD implants, follow-up, and therapies. Electronic medical records were systematically reviewed by 3 coinvestigators (K.D., N.G., and M.R.), and the following variables were extracted using a data abstraction form to ensure consistency: demographic information, including age, sex, weight, systolic blood pressure on day of implant, list of comorbidities, medications, and laboratory tests, that will allow calculation of modified Seattle heart failure model score (differential ICD benefit Seattle heart failure model score-D) and Charlson comorbidity index score, relevant echocardiographic data (ejection fraction within 3 months of implant procedure) or other imaging modality that estimated ejection fraction, and baseline electrocardiographic data at the time of device implant. A Seattle heart failure model score heart failure model score-D score was calculated for every patient at the time of device implant, as described by Levy et al, as well as a Charlson comorbidity index, as described by Charlson et al. Seattle heart failure model score-D was chosen because data were missing for variables, such as lymphocyte count and uric acid levels. 15 ICD therapies as adjudicated by the physicians caring for the patients were extracted from the electrophysiology database and electronic medical record. The cohort of eligible veterans was defined as those (1) with ≥18 years of age, (2) who received ICD/CRT-defibrillator devices according to the guidelines current at the time of ICD implantation for primary prevention of sudden cardiac death or secondary prevention of sudden cardiac death, (3) whose devices were implanted at the VAPORHCS. Patients were excluded if devices were implanted outside the VAPORHCS and if routine device follow-up occurred outside the VAPORHCS clinics. Figure 1 is a flowchart that shows the study profile diagram. Duration of follow-up was defined as the period from the time of implantation to the last device follow-up visit, until death or if they were lost to follow-up or crossed-over from one clinic follow-up model to the other. Loss to followup occurred if patients switched to follow-up at a different VA device clinic (other than VAPORHCS) or a different healthcare system. Time intervals beyond crossover points were censored from analysis. Different device companies developed remote interrogation/monitoring capabilities at different times. Both TMVC and CIC patients were enrolled in remote monitoring programs as they became available.
Study End Points
The primary outcome of the study compared time to first appropriate ICD therapy. The secondary outcomes were overall survival, time to first inappropriate ICD therapy, and time to first ICD shock.
Statistical Analysis
The primary noninferiority hypothesis required that the TMVC group preserve ≤10% point difference in cumulative incidence rate of each outcome to prove noninferior to the conventional group. The 10% point difference was arbitrary chosen. Medical and demographic characteristics were summarized using means and SDs for continuous variables and frequencies and percentages for categorical variables. Charlson comorbidity score was summarized with a median and interquartile range because of its semiquantitative nature. Independent t tests (modified to use robust standard errors), rank-sum tests, and χ 2 tests were used to compare characteristics between CIC and TMVC groups, with statistical significance set to 0.05. Time to death and time to ICD therapy end points (unadjusted for patient characteristics) was addressed using Kaplan-Meier estimates. Tests of noninferiority (assuming TMVC is inferior to CIC until data demonstrates the opposite) were based on the difference in estimates of survival (or incidence) at 6 months, 1 year, 3 years, 5 years, and 7 years of followup, and all tests used a 10% point margin of noninferiority. Formal tests of equivalence were not reported beyond 7 years because of sparseness of data. Analyses used the full data set out to 14.4 years for all tests and inferences, but figures generated have been curtailed to 10 years of follow-up. Cox proportional hazard (PH) models were used to investigate how patient characteristics affected survival and ICD therapies. Continuous and semicontinuous covariates were included in the model using restricted cubic splines with knots (k=4) placed at the 5th, 35th, 65th, and 95th percentile of a given covariate; binary indicator variables were used to model categorical factors. All Cox PH models retained age and treatment group, regardless of significance, but other variables were excluded as needed based on supervised backward elimination from an initial model that included all potential explanatory variables. The final parsimonious multivariable model for each outcome included covariates that were significant at the P≤0.10 and the PHs assumption was assessed through plots of scaled Schoenfeld residuals and the Grambsch-Therneau test. Regression of pseudovalues derived from Kaplan-Meier estimates was used to conduct noninferiority tests adjusted for those characteristics identified through the Cox PH models at the same 5 follow-up times and with the stated margin of noninferiority. 16 Estimated survival (or incidence) corresponds to fitted values from these regression models of pseudovalues when relevant covariates are set to their mean value and factors set to their baseline level. All analyses were performed using Stata (version 14.1; StataCorp, LP, College Station, TX) and the stpsurv module.
RESULTS
Baseline Characteristics
Our analysis included a total of 523 patients of whom 236 patients were followed-up at the CIC, and 287 patients were followed-up at the TMVC. Mean duration of follow-up was 1763. 
Primary Outcomes
The median time at risk for the primary outcome of appropriate ICD therapy was 1.61 years (maximum 13.4 years) for 236 persons followed in the CIC model and was 1.74 years (maximum 13.0 years) among 287 individuals followed in the TMVC model. There was no statistically significant difference in cumulative incidence of appropriate ICD therapy between the groups either early (X 1 2 =0.18; P=0.68; Peto-Peto test) or late during follow-up (X 1 2 =0.15; P=0.70; log-rank test). Figure 2 shows the Kaplan-Meier curves of the cumulative incidence during time of the primary end point. Tests for noninferiority found patients followed by TM trended to have a lower risk of appropriate ICD therapy with the upper limit of the confidence being less than the prespecified 10% difference for noninferiority at all time points (6 months, 1 year, 3 years, 5 years, and 7 years) that were evaluated (Table IIA in the Data Supplement). Multivariable Cox PH models were run that included covariates with a P value of ≤0.10 and identified age, ejection fraction, digoxin use, and indication of ICD implantations (primary prevention ICD) as variables significantly associated with appropriate ICD therapies (Table IIB in the Data Supplement). After adjusting for these variables, the noninferiority criterion was still met for all prespecified time points (Table 1) .
Secondary Outcomes
Mortality Kaplan-Meier curves of survival showed no significant difference between groups, either early on (X 1 2 =0.90; P=0.34; Peto-Peto test) or later during follow-up (X 1 2 =0.78; P=0.38; log-rank test) as shown in Figure 3 . Median time at risk was 4.45 years (maximum of 13.4 years) for 236 people followed in person and was 4.42 years (maximum 14.4 years) among 287 individuals followed in the TMVC group. There were 111 and 125 deaths observed in the CIC and TMVC groups, respectively. Unadjusted specific tests for noninferiority (at 0.5, 1, 3, 5, and 7 years of follow-up) indicated TMVC follow-up is not inferior to CIC followup (P<0.05). For the first 7 years, survival is noted to trend slightly higher for TMVC than for CIC follow-up and, at worst, survival for those followed via video conferencing is estimated to be at most 5.9% points less (1-sided 95% confidence limit) than survival for those followed in person, which is within the 10% points margin of noninferiority (Table IIIA in the Data Supplement). Multivariable Cox PH models for overall survival identified age, Seattle heart failure model score-D score, Charlson score, use of digoxin, and history of diabetes mellitus as significant risk factors (Table IIIB in the Data Supplement). After adjustment, adjusted specific tests for noninferiority indicated TMVC follow-up is not inferior to CIC follow-up (P<0.05) through the first 7 years ( Adjusted noninferiority tests comparing incidence of appropriate shocks between CIC and TMVC groups at 6 mo, 1, 3, 5, and 7 y of followup. Estimated survival is adjusted to reflect a 64-y-old individual with ejection fraction of 27%, and other drug and medical histories set to reference values. Margin of noninferiority is 10% points, and a significant P value implies one can reject the idea of TMVC being inferior to CIC follow-up. CI (2-sided 90% coverage; 1-sided 95% coverage) estimates a reasonable range for the difference in incidence between groups, and the upper limit must be <+0.10 to declare noninferiority. CI indicates confidence interval; CIC, conventional in-person clinic; ICD, implantable cardioverter-defibrillator; and TMVC, telemedicine video-conferencing clinic. Figure 4B ). There were 126 and 159 patients with ICD shocks observed in the CIC and TMVC groups, respectively. In an unadjusted setting, TMVC was noninferior to CIC (P<0.05) during the first 4 time points explored (through 5 years of follow-up), but the CIs were wider and noninferiority was not met at 7 years (Table VA in the Data Supplement). Multivariable Cox PH model showed that age, QRS duration, use of digoxin, history of atrial fibrillation, and indication for ICD implantation (primary prevention) were significant risk factors (Table VB in the Data Supplement). After controlling for these important covariables, tests of noninferiority showed that TMVC is not inferior to CIC follow-up (P<0.05) only at 1 and 3 years of follow-up (Table 4) .
Inappropriate Therapies
DISCUSSION
We examined clinical outcomes for device follow-up between a unique form of device follow-up using videoconferencing TM and the conventional in-person followup model that is routinely used in clinical practice. This is the first chart review study to compare clinical outcomes between the aforementioned device follow-up models with a long duration of follow-up. The main findings of this study were that device follow-up by TMVC, when compared with CIC device follow-up, was noninferior Adjusted noninferiority tests comparing survival between CIC and TMVC groups at 6 mo, 1, 3, 5, and 7 y of follow-up. Estimated survival is adjusted to reflect a 64-y-old individual with Charlson score of 6, SHFM-D score of 0, not taking digoxin and with history of diabetes mellitus. Margin of noninferiority is 10% points, and a significant P value implies one can reject the idea of TMVC being inferior to CIC follow-up. CI (2-sided 90% coverage; 1-sided 95% coverage) estimates a reasonable range for the difference in survival between groups, and the lower limit must be >−0.10 to declare noninferiority. CI indicates confidence interval; CIC, conventional in-person clinic; SHFM-D, Seattle heart failure model score; and TMVC, telemedicine video-conferencing clinic.
with respect to the primary outcome of appropriate ICD therapies during early and late follow-up, as well as the secondary outcomes of overall survival in the first 7 years of follow-up, incidence of inappropriate therapies, and time to first ICD shock in the first 5 years of follow-up. These end points were chosen because the net effect of the optimization of ICD programming and general cardiology care that occurs in ICD clinics is directly reflected in these outcomes. Optimal programming has been shown to minimize the risk of both appropriate and inappropriate therapy and improve mortality. [17] [18] [19] Similarly, the optimization of general cardiology care should minimize the risk of decompensated heart failure that could also lead to a reduction in appropriate and inappropriate ICD therapy. Finally, ICD shocks are a prime driver of patient satisfaction and anxiety, and minimizing the risk of shocks is an important goal of all ICD follow-up programs.
The main observation that there is no difference in clinical outcomes between the 2 models suggests TMVC offers a safe and reliable solution for the delivery of ICD follow-up care to patients who live long distances from electrophysiology specialty centers. Implantation of devices with wireless remote monitoring will allow continuous monitoring, providing daily self-testing, better event notifications for out-of-bound parameters, and earlier detection of actionable events. 8 Although the use of remote interrogation will help reduce the volume of in-person visits, [20] [21] [22] [23] [24] the need for in-person follow-up to address recurrent ICD shocks, out-of bound parameters, adjust programming/medication, and clinical evaluation will continue to be required and needed. The TMVC model can offer an alternative to in-person device follow-up for patients in remote areas where electrophysiology subspecialty care is not available.
TMVC device follow-up reduces travel time and travel cost for patients and providers. Reimbursement is the same whether the visit is in-person or telemedicine and is based on individual contracts with the commercial payors. Data for fiscal year 2016 showed that VAPORHCS did a total of 1308 TMVC visits saving an estimated 238 000 miles of patient travel. The large geographic area covered by VAPORHCS leads to Adjusted noninferiority tests comparing incidence of inappropriate therapies between CIC and TMVC groups at 6 mo,1, 3, 5, and 7 y of follow-up. Estimated incidence is adjusted to reflect a 64-y-old individual with QRS of 118 ms, ejection fraction of 27%, and other drug and medical histories set to reference values. Margin of noninferiority is 10% points, and a significant P value implies one can reject the idea of TMVC being inferior to CIC follow-up. CI (2-sided 90% coverage; 1-sided 95% coverage) estimates a reasonable range for the difference in incidence between groups and the upper limit must be <+0.10 to declare noninferiority. CI indicates confidence interval; CIC, conventional in-person clinic; and TMVC, telemedicine video-conferencing clinic a larger number of miles saved per patient than other clinics might realize. However, the patient centric value of care and patients' convenience resulting from this type of clinic cannot be underestimated. For providers, TM clinics will save travel time compared with traveling to rural areas to do clinics. TM clinics can also allow some additional benefits at the provider end by providing efficiencies in the use of constrained resources, such as clinic space, nursing staff, and other infrastructure. TM is an example of a flexible model that can overcome constrained resource allocation challenges. In this light, telehealth programs in the VA and non-VA health systems have proven to be cost-effective.
14,25 Potential cost savings from using this model in a wide range of healthcare systems may be significant.
Limitations
The data may not represent veterans or nonveterans in other geographic locations. Few female veterans were represented (<1%); therefore, extrapolation of these results to a female ICD recipient population is precluded. Limitations inherent in retrospective studies, which include but are not limited to incomplete documentation, variation in interpretation of data, and missing data verification, should be considered when interpreting our results. However, previous studies have shown that VA medical data sets are generally reliable. 26 Our study did not investigate the number of heart failure hospitalizations because data for hospitalizations outside the VA system were not available to us. However, one would expect the efficacy of heart failure control to be reflected in virtually all of our end points suggesting that heart failure treatment was noninferior in the patients followed in the TMVC.
Conclusions
TM ICD follow-up, using video conferencing for patients in areas where electrophysiology subspecialty care is not available, offers a long-term device follow-up model that leads to clinical outcomes that are noninferior to the conventional in-person follow-up. This model has potential cost savings in reducing travel time and cost for patients and providers, as well as providing a potential solution for constrained clinic space and resource utilization. Further research in the form of a prospective randomized clinical trial and cost-effectiveness study is needed to confirm or refute the findings in our study. 
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